Figure 1.

Patient disposition. ^†Following an announcement of a possible increase in CV risk with celecoxib, some patients withdrew consent (4%) and some (12.9%) were discontinued after a protocol amendment excluded patients with an elevated CV risk or a history of CV or cerebrovascular disease; o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat.